Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrin Schaudig

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Thrombosis and Haemostasis|March 30, 2007
Hormonal therapy with patch or pill: how much does it matter?Katrin Schaudig, Christoph Thomssen
Women'S Health (London, England)|August 6, 2019
Hormone therapy for first-line management of menopausal symptoms: Practical recommendationsSantiago Palacios, John C Stevenson, Katrin Schaudig, et al.
Women'S Health (London, England)|April 3, 2026
Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT studyMarla Shapiro, Rossella E Nappi, Xuegong Wang, et al.
Expert Review of Clinical Pharmacology|June 6, 2023
Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspectiveSerge Rozenberg, Nick Panay, Marco Gambacciani, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 18, 2020
Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trialPeyman Hadji, Joseph Neulen, Katrin Schaudig, et al.
The Journal of Sexual Medicine|November 6, 2023
Couplepause: deconstructing sick menopause and andropause during midlifeSerge Rozenberg, Rossella E Nappi, Katrin Schaudig, et al.
Maturitas|January 14, 2025
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapyMarla Shapiro C M, Xi Wu, Xuegong Wang, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|September 1, 2024
Time-efficient consultation hours in the department of gynecological endocrinologyAnne-Sophie Berger, Marina Sourouni, Norman Bitterlich, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Thrombosis and Haemostasis|March 30, 2007
Hormonal therapy with patch or pill: how much does it matter?Katrin Schaudig, Christoph Thomssen
Women'S Health (London, England)|August 6, 2019
Hormone therapy for first-line management of menopausal symptoms: Practical recommendationsSantiago Palacios, John C Stevenson, Katrin Schaudig, et al.
Women'S Health (London, England)|April 3, 2026
Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT studyMarla Shapiro, Rossella E Nappi, Xuegong Wang, et al.
Expert Review of Clinical Pharmacology|June 6, 2023
Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts' perspectiveSerge Rozenberg, Nick Panay, Marco Gambacciani, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 18, 2020
Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trialPeyman Hadji, Joseph Neulen, Katrin Schaudig, et al.
The Journal of Sexual Medicine|November 6, 2023
Couplepause: deconstructing sick menopause and andropause during midlifeSerge Rozenberg, Rossella E Nappi, Katrin Schaudig, et al.
Maturitas|January 14, 2025
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapyMarla Shapiro C M, Xi Wu, Xuegong Wang, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|September 1, 2024
Time-efficient consultation hours in the department of gynecological endocrinologyAnne-Sophie Berger, Marina Sourouni, Norman Bitterlich, et al.
Geburtshilfe Und Frauenheilkunde|September 27, 2021
Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Geburtshilfe Und Frauenheilkunde|December 13, 2022
Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg DrospirenoneThomas Römer, Johannes Bitzer, Christian Egarter, et al.
Pageof 2